Genes differentially expressed in prostate cancer [1]

BJU International

Volumn 94, Issue 6, 2004, Pages 937-938

  Pitts Jr , Walter Reid ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE;

CANCER GRADING; EPITHELIUM CELL; GENE EXPRESSION REGULATION; HIGH RISK POPULATION; LETTER; OBESITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; STROMA CELL; TUMOR RECURRENCE;

DIHYDROTESTOSTERONE; HUMANS; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 8144227338     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410x.05132_1.x     Document Type: Letter

References (17)

1. Eder IE, Bektic J, Haag P, Bartsch G, Klocker H. Genes differentially expressed in prostate cancer. BJU Int 2004; 93: 1151-5
2. Luo J, Dunn TA, Walsh PC et al. Decreased gene expression of steroid 5 alpha reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate cancer. The Prostate 2003; 57: 134-9
3. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. NEJM 2003; 349: 213
4. Liang T, Lino S. Inhibition of steroid 5 alpha reductase by specific aliphatic unsaturated fatty acids. Biochem J 1992; 285: 557-62
5. Fair WR. Back to the future-the role of complementary medicine in urology. J Urol 1999; 162: 411
6. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthetase (FAS) with antitumor activity. Cancer Research 2004; 64: 2070-5
7. Ross RK, Bernstein L, Lobo RA et al. 5 alpha reductase activity and risk of prostate cancer among Japanese and U.S. white and black males. Lancet 1992; 339: 887
8. Carron KK, Khor HT. Dietary fat in relation to tumor-genesis. Prog Biochem Pharmacol 1975; 10: 308
9. Amling CL, Riffenburgh RH, Sun L et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004; 22: 431-45
10. Reichardt JK, Makridakis N et al. Genetic variability of human SRD5AZ gene: Implications for prostate cancer risk. Cancer Res 1995; 55: 3973
11. Lemack GE, Poppas DP, Vaughan ED. Urologic causes for gynecomastia. Urology 1995; 45: 313-9
12. DeMarzo AM, Marchi VL, Epstein J, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostate carcinogenesis. Am J Pathol 1999; 155: 1985
13. Coffey DS. Similarities of prostate and breast cancer. Evolution, diet and estrogens. Urology 2001; 57 (Suppl. 4A): 31
14. Chang SM, Chung LWK. Interaction by prostatic fibroblast and epithelial cells in culture. The role of androgens. Endocrinology 1989; 125: 2719
15. Ramen JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002; 167: 624-9
16. Scherr D, Pitts WR, Jr Vaughan ED Jr. Diethylstilbestrol (DES) revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 2002; 167: 535
17. Steiner MS, Raghow S, Neubauer BL. Selective estrogen receptor modulators for the chemoprevention of prostate cancer. Urology 2001; 57 (Suppl. 4A): S68-S72